GlaxoSmithKline
Great West Road
Brentford
Middlesex
TW8 9BD
United Kingdom
Phone:
020-8975-2000-U-K-or-800-366-8900-U-S
Fax:
|
GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment.
GSK's mission is to improve the quality of human life by enabling people to do more, feel better and live longer.
Headquartered in the UK and with operations based in the US, the new company is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market.
GSK also has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products.
The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders.
Based on 2000 Preliminary Annual Results, GSK had sales of £18.1 billion ($27.5 billion) and profit before tax of £5 billion ($8.1 billion). Pharmaceutical sales accounted for £15.4 billion ($23.5 billion), 85 per cent of the total.
GSK had four products with sales of over $1 billion and a total of 16 products with sales in excess of $500 million.
GSK has over 100,000 employees worldwide. Of these, over 40,000 are in sales and marketing, the largest sales force in the industry. Almost 40,000 employees work at 108 manufacturing sites in 41 countries and over 16,000 are in R&D.
Last Updated 11-01-01
Email:
Ownership:
Public
Web Site:
GlaxoSmithKline
Employees:
Symbol: GSK
|
| Collaborations |
|
Beyond Genomics, Inc.
|
|
AVANIR Pharmaceuticals
|
|
Pharmagene Laboratories Limited
|
|
Aradigm Corporation
Agreement to develop AERx technology for the delivery of morphine and fentanyl for pain management.
|
|
CuraGen Corporation (Acquired by Celldex Therapeutics, Inc.)
Product Discovery and Pharmacogenomics
|
|
Paratek Pharmaceuticals, Inc.
|
|
Agenus (Formerly known as Antigenics Inc. - New York)
|
|
ChemoCentryx, Inc.
|
|
Gilead Sciences, Inc.
|
|
Gilead Sciences, Inc. (Seattle, WA)
|
|
Gilead Sciences, Inc. (Durham, NC)
|
|
MedImmune
|
|
Vertex Pharmaceuticals (MA)
(VX-409 and Backup Compounds)
|
|
Ligand Pharmaceuticals Inc.
- In 1995, we entered into a research and development collaboration with SmithKline Beecham (now GlaxoSmithKline) to use our proprietary expertise to discover and characterize small-molecule, orally bioavailable drugs to control hematopoiesis (the formation and development of blood cells) for the treatment of a variety of blood cell deficiencies. Eltrombopag and a back up compound, SB-559448, resulted from this collaboration. These compounds are orally active, non-peptide, small molecule thrombopoietin (TPO) mimetics for the treatment of thrombocytopenia (low platelet counts). Eltrombopag is in Phase III clinical trials for immune thrombocytopenic purpura (ITP). GlaxoSmithKline plans to file an NDA for the ITP indication in late 2007/early 2008. A Phase III clinical trial in patients with hepatitis C is planned in 2H07. In addition, Phase I/II studies are ongoing in patients with chemotherapy-induced thrombocytopenia. The backup compound, SB-559448, is in Phase I clinical trials.
|
|
EPIX Pharmaceuticals, Inc.
|
|
|